Loading...
•
Sep 30, 2022
Bridgebio Q3 2022 Earnings Report
BridgeBio reported its Q3 2022 financial results and business update, highlighting pipeline progress and expense reduction.
Key Takeaways
BridgeBio Pharma reported a decrease in operating expenses by 15.9% compared to Q2 2022, alongside positive data updates for its LGMD2i and KRAS programs. The company ended the quarter with $558.3 million in cash, providing financial runway into 2024.
Reported positive preclinical data for KRASG12C GTP/GDP dual inhibitor development candidate, BBO-8520, and for its novel PI3Kα:RAS breaker mechanism.
Reported positive updated 12-month Phase 2 data for BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i.
Reported dosing of first lung cancer patient in Phase 1/2 trial of SHP2 inhibitor BBP-398 in combination with Amgen’s Lumakras (sotorasib).
Ended quarter with $558.3 million in cash, cash equivalents and marketable securities, providing financial runway into 2024.
Forward Guidance
BridgeBio anticipates continued decline in cash burn in Q4 due to potential business development and restructuring activities, expecting cash runway into 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...